Prognostic score for Pneumocystis carinii pneumonia. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Prognostic score for Pneumocystis carinii pneumonia.

Respiration. 1990;57(4):259-63. Unique Identifier : AIDSLINE MED/91252607
Speich R; Weber R; Kronauer CM; Opravil M; Luthy R; Russi EW; Department of Internal Medicine, University Hospital of Zurich,; Switzerland.

Abstract: Sixty episodes of Pneumocystis carinii pneumonia in 59 patients were evaluated for risk factors predicting fatal outcome within 14 days after bronchoscopy. We found significantly higher values for serum lactate dehydrogenase (p less than 0.001), alveolar-arterial oxygen difference (p less than 0.001) and percentage of bronchoalveolar lavage neutrophils (p less than 0.001) in patients dying within 14 days, but there was considerable overlap of these variables between the two groups. Using a score system combining the three parameters allowed however an excellent discrimination between the two groups.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Bronchoalveolar Lavage Fluid/PATHOLOGY Comparative Study Female Human Lactate Dehydrogenase/BLOOD Male Opportunistic Infections/COMPLICATIONS/*MORTALITY Oxygen/BLOOD Pneumonia, Pneumocystis carinii/COMPLICATIONS/*MORTALITY Prognosis Risk Factors JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDcomplicationsadultbronchoalveolarlavagefluid/pathologycomparativestudyfemalehumanlactatedehydrogenase/bloodmaleopportunisticinfections/complications/KWDmortalityoxygen/bloodpneumonia,pneumocystiscarinii/complications/KWDmortalityprognosisriskfactorsjournalarticle
910930
M9190677

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .